Results 11 to 20 of about 9,263,948 (394)
Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma. [PDF]
, 2020 Introduction: the high cure rates achieved in early-stage (ES) Hodgkin lymphoma (HL) are one of the great successes of hemato-oncology, but late treatment-related toxicity undermines long-term survival.
Barrington, SF +11 more
core +2 more sources
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]
, 2016 Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S. +17 more
core +5 more sources
Human Vaccines & Immunotherapeutics, 2023 Individuals who are immunocompromised (IC) due to therapy or underlying disease are at increased risk of herpes zoster (HZ). This study evaluates the public health impact of recombinant zoster vaccine (RZV) relative to no HZ vaccination for the ...
Desmond Curran +8 more
doaj +1 more source
Composite follicular lymphoma and classic Hodgkin lymphoma [PDF]
Journal of Pathology and Translational Medicine, 2022 Composite lymphoma is very rare and a combination of Hodgkin lymphoma and non-Hodgkin lymphoma and even histiocytic tumors can occur. Because of the unfamiliarity, not only can this cause diagnostic problems, but can also affect treatment plan. We report
Han-Na Kim +5 more
doaj +1 more source
Blood, 2018 The rarity of neoplastic cells in the biopsy imposes major technical hurdles that have so far limited genomic studies in classical Hodgkin lymphoma (cHL).
V. Spina +36 more
semanticscholar +1 more source
Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year followup in the West of Scotland Cancer Network [PDF]
, 2011 Clinically and biologically, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has much more in common with germinal-center derived B-cell non-Hodgkin lymphoma (NHL) than with classical Hodgkin lymphoma (cHL).
Diehl V +8 more
core +1 more source
Serum biomarkers and clinical characteristics of patients with Hodgkin lymphoma [PDF]
Vojnosanitetski Pregled, 2018 Background/Aim. In classical Hodgkin’s lymphoma (cHL) the existing prognostic scoring systems do not include markers that adequately reflect the interaction of malignant Hodgkin and Reed-Sternberg (HRS) cells and tumor environment.
Simonović Olivera +6 more
doaj +1 more source
Journal of Clinical Oncology, 2014 The purpose of this work was to modernize recommendations for evaluation, staging, and response assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).
B. Cheson +6 more
semanticscholar +1 more source
Eosinophilia as a first sign of Hodgkin´s lymphoma: A case report [PDF]
Vojnosanitetski Pregled, 2017 Introduction. It is well known that eosinophilia appears in a malignant disease. Frequency of all Hodgkin`s lymphoma patients is estimated to about 15%. Prognostic importance of this phenomenon is not completely investigated.
Milošević Rajko +3 more
doaj +1 more source
Primary mediastinal lymphoma: diagnosis and treatment options. [PDF]
, 2014 Primary mediastinal large B-cell lymphoma (PMBCL) is a unique B-cell lymphoma variant that arises from a putative thymic medulla B cell. It constitutes 2-4% of non-Hodgkin lymphomas and occurs most frequently in young females. PMBCL is characterized by a
DI ROCCO, Alice +4 more
core +1 more source